$1.52
-0.01-0.65%
At close: Nov 13, 4:00 PM EST
$1.47
-0.05-3.29%
After Hours: 4:00 PM EST
Inhibikase Therapeutics Inc
IKTNASDAQ
Inhibikase Therapeutics fell 4.4% from $1.60 to $1.53, behind the S&P 500's +12.3%. Its worst day was Jan 8 (−11.6%), and its low came Dec 3 at $1.44.
Nov 13, 2025 – Nov 12, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.13 missed the $-0.12 estimate on $0.00 revenue.
−0.7% · S&P 500 −0.9%
Inhibikase Therapeutics closed at its lowest level of the year, 10.0% below where the year started.
Story events cover the past 12 months · Times ET
−5.3% · S&P 500 +0.1%
Inhibikase Therapeutics shares rose 21.2%, while the S&P 500 fell 0.0%.
+21.2%, the year's best day · S&P 500 0.0%
Inhibikase Therapeutics shares fell 11.6%, while the S&P 500 fell 0.0%.
−11.6%, the year's worst day · S&P 500 0.0%
Inhibikase Therapeutics shares rose 13.9%, while the S&P 500 rose 0.7%.
+13.9% · S&P 500 +0.7%
EPS of $-0.10 beat the $-0.12 estimate on $0.00 revenue.
+3.1% · S&P 500 −1.7%
EPS of $-0.10 beat the $-0.10 estimate on $0.00 revenue.
−1.0% · S&P 500 +0.6%
EPS of $-0.11 missed the $-0.09 estimate on $0.00 revenue.
−2.0% · S&P 500 +0.3%
Inhibikase Therapeutics closed at its highest level of the year, 57.5% above where the year started.
+0.8% · S&P 500 +1.0%
EPS of $-0.10 beat the $-0.12 estimate on $0.00 revenue.
+5.2% · S&P 500 +1.3%
Where it ended: a close of $1.53 on Nov 12, 2026.
Nothing in the past 12 months.
All IKT dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for IKT and SPY from Benzinga historical bars. Not investment advice.
